Paul I. Nadler

1.4k total citations
49 papers, 1.0k citations indexed

About

Paul I. Nadler is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Paul I. Nadler has authored 49 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Immunology and 11 papers in Epidemiology. Recurrent topics in Paul I. Nadler's work include Immune Cell Function and Interaction (9 papers), HER2/EGFR in Cancer Research (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Paul I. Nadler is often cited by papers focused on Immune Cell Function and Interaction (9 papers), HER2/EGFR in Cancer Research (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Paul I. Nadler collaborates with scholars based in United States, Canada and Switzerland. Paul I. Nadler's co-authors include Richard J. Hodes, Gerald B. Ahmann, Debra L. Wood, Mark D. Tolpin, Ralf Klingenstein, Lars Östberg, Paul H. Ehrlich, Donald M. Gibson, Zeinab A. Moustafa and Robert J. Wills and has published in prestigious journals such as Science, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Paul I. Nadler

48 papers receiving 966 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul I. Nadler United States	20	326	300	243	222	190	49	1.0k
J Zeromski Poland	19	537 1.6×	159 0.5×	255 1.0×	265 1.2×	103 0.5×	98	1.2k
Anja Dankof Germany	15	348 1.1×	155 0.5×	267 1.1×	480 2.2×	98 0.5×	26	1.3k
Jennifer Watkins United Kingdom	20	300 0.9×	567 1.9×	450 1.9×	434 2.0×	136 0.7×	58	1.5k
J P Lamelin France	18	375 1.2×	311 1.0×	128 0.5×	208 0.9×	230 1.2×	42	1.0k
J Fujimoto Japan	16	253 0.8×	105 0.3×	152 0.6×	282 1.3×	66 0.3×	30	897
K. Witter Germany	15	397 1.2×	195 0.7×	415 1.7×	213 1.0×	52 0.3×	57	957
Ronald R. Nepomuceno United States	15	454 1.4×	330 1.1×	281 1.2×	270 1.2×	60 0.3×	20	1.1k
K-H Meyer zum Büschenfelde Germany	14	399 1.2×	523 1.7×	87 0.4×	145 0.7×	461 2.4×	19	1.4k
Steven D. Bines United States	16	230 0.7×	168 0.6×	636 2.6×	244 1.1×	159 0.8×	26	1.1k
A. Bohbot France	16	647 2.0×	147 0.5×	141 0.6×	362 1.6×	75 0.4×	40	1.1k

Countries citing papers authored by Paul I. Nadler

Since Specialization

Citations

This map shows the geographic impact of Paul I. Nadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul I. Nadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul I. Nadler more than expected).

Fields of papers citing papers by Paul I. Nadler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul I. Nadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul I. Nadler. The network helps show where Paul I. Nadler may publish in the future.

Co-authorship network of co-authors of Paul I. Nadler

This figure shows the co-authorship network connecting the top 25 collaborators of Paul I. Nadler. A scholar is included among the top collaborators of Paul I. Nadler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul I. Nadler. Paul I. Nadler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berlin, Jordan, Anthony W. Tolcher, Jennifer G. Whisenant, et al.. (2022). First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. Investigational New Drugs. 40(3). 586–595. 8 indexed citations

Yap, Timothy A., Nehal J. Lakhani, Daniel Vilarim Araújo, et al.. (2020). AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3587–3587. 21 indexed citations

Bardelli, Alberto, Thomas T. Poulsen, Rodrigo Dienstmann, et al.. (2017). Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004. Annals of Oncology. 28. v34–v34. 1 indexed citations

Dragovich, Tomislav, Mark S. Huberman, Daniel D. Von Hoff, et al.. (2006). Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemotherapy and Pharmacology. 60(2). 295–303. 40 indexed citations

Nadler, Paul I., et al.. (2006). An interactive computer kiosk module for the treatment of recurrent uncomplicated cystitis in women. Journal of General Internal Medicine. 21(11). 1156–1159. 13 indexed citations

Ehrlich, Paul H., et al.. (1992). Genetic Alterations in the Gene Encoding the Major Hbsag: Dna and Immunological Analysis of Recurrent Hbsag Derived From Monoclonal Antibody—Treated Liver Transplant Patients. Hepatology. 15(5). 757–766. 143 indexed citations

Mittelman, Abraham, Carmelo Puccio, Debra L. Wood, et al.. (1992). A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Investigational New Drugs. 10(3). 183–190. 30 indexed citations

Nadler, Paul I., et al.. (1991). Safety and Tolerability of Two Percent Cyclosporine (Sandimmune ^® ) Ophthalmic Ointment in Normal Volunteers. Journal of Ocular Pharmacology and Therapeutics. 7(4). 301–312. 8 indexed citations

Drobyski, William R., Mark S. Gottlieb, Donald R. Carrigan, et al.. (1991). PHASE I STUDY OF SAFETY AND PHARMACOKINETICS OF A HUMAN ANTICYTOMEGALOVIRUS MONOCLONAL ANTIBODY IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS. Transplantation. 51(6). 1190–1196. 25 indexed citations

10.

Nokta, Mostafa, et al.. (1991). In Vivo Administration of Tumor Necrosis Factor- is Associated with Antiviral Activity in Human Peripheral Mononuclear Cells. Experimental Biology and Medicine. 197(2). 144–149. 10 indexed citations

11.

Winston, Drew J., L J Eron, Monto Ho, et al.. (1988). Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. The American Journal of Medicine. 85(2). 147–151. 24 indexed citations

12.

Witter, Frank R., et al.. (1988). Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in humans. Clinical Pharmacology & Therapeutics. 44(2). 239–243. 6 indexed citations

13.

Conkling, Paul, Cynthia C. Chua, Paul I. Nadler, et al.. (1988). Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.. PubMed. 48(19). 5604–9. 26 indexed citations

14.

Witter, Frank R., Diane E. Griffin, Paul I. Nadler, et al.. (1987). Time Course of Interferon Levels, Antiviral State, 2′,5′-Oligoadenylate Synthetase and Side Effects in Healthy Men. Journal of Interferon Research. 7(1). 29–39. 28 indexed citations

15.

Nadler, Paul I.. (1985). Reply to Dr. Mitchell. Human Pathology. 16(1). 98–98. 1 indexed citations

16.

Miller, G G, Paul I. Nadler, Richard J. Hodes, & D H Sachs. (1982). Modification of T cell antinuclease idiotype expression by in vivo administration of anti-idiotype.. The Journal of Experimental Medicine. 155(1). 190–200. 12 indexed citations

17.

Reichert, Cheryl M., et al.. (1982). High-resolution zone electrophoresis, combined with immunofixation, in the detection of an occult myeloma paraprotein.. Clinical Chemistry. 28(11). 2312–2313. 13 indexed citations

18.

Ahmann, Gerald B., et al.. (1981). T cell recognition in the mixed lymphocyte response. II. Ia-positive splenic adherent cells are required for non-I region-induced stimulation.. The Journal of Immunology. 127(6). 2308–2313. 33 indexed citations

19.

Miller, G G, Paul I. Nadler, Yoshihiro Asano, Richard J. Hodes, & David H. Sachs. (1981). Induction of idiotype-bearing, nuclease-specific helper T cells by in vivo treatment with anti-idiotype.. The Journal of Experimental Medicine. 154(1). 24–34. 27 indexed citations

20.

Nadler, Paul I., Ralf Klingenstein, & R J Hodes. (1980). Ontogeny of murine accessory cells: Ia antigen expression and accessory cell function in in vitro primary antibody responses.. The Journal of Immunology. 125(2). 914–920. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact